GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

BACKGROUND: Neuroblastoma is the most common extracranial solid tumor of childhood. Patients with high-risk disease undergo extremely aggressive therapy and nonetheless have cure rates below 50%. Treatment with the ch14.18 monoclonal antibody (dinutuximab beta), directed against the GD2 disialogangl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Zirngibl, Felix, Ivasko, Sara M, Grunewald, Laura, Klaus, Anika, Schwiebert, Silke, Ruf, Peter, Lindhofer, Horst, Astrahantseff, Kathy, Andersch, Lena, Schulte, Johannes H, Lode, Holger N, Eggert, Angelika, Anders, Kathleen, Hundsdoerfer, Patrick, Künkele, Annette
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Oncolytic and Local Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8292814/
https://ncbi.nlm.nih.gov/pubmed/34285106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002923
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados